Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Moderate Buy" from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-three research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eighteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $167.41.

SRPT has been the topic of several analyst reports. HC Wainwright reaffirmed a "sell" rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday. Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th.

Sarepta Therapeutics Trading Up 0.9 %

SRPT stock traded up $0.65 during trading on Monday, hitting $74.10. 2,591,321 shares of the company traded hands, compared to its average volume of 1,218,291. The company has a 50-day moving average of $107.19 and a 200-day moving average of $118.00. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a 1 year low of $73.05 and a 1 year high of $173.25. The firm has a market capitalization of $7.19 billion, a PE ratio of 59.28 and a beta of 0.79.

Remove Ads

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Manchester Capital Management LLC boosted its stake in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank raised its position in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after buying an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics in the 4th quarter worth about $36,000. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.